Synchronous Thyroid and Gastric Mantle Cell Lymphoma

Introduction: Mantle cell lymphoma (MCL) is a distinct entity within the World Health Organization classification of lymphoid neoplasm and represents approximately 8% of lymphoma. Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multiple lymph nodes as well as the spleen, bone marrow, blood, and gastrointestinal tract. MCL of the thyroid occurs exceptionally. The MCL of the stomach is also an exceptional occurrence. Observation: We describe the case of a 58-year-old male who was diagnosed with thyroid and gastric MCL. The patient was classified into high risk group according to the Mantle Cell Lymphoma International Prognostic Index (MIPI). The R-CHOP (Rituximab, Cyclophosphamide, Adriablastine, Vincristine and Prednisone) regimen was started and complete remission was achieved after 8 Case Study Zahra et al.; IJMPCR, 8(1): 1-6, 2016; Article no.IJMPCR.29229 2 courses. He currently receives a maintenance treatment with rituximab every two months. Conclusion: This case is a combination of two rather infrequent extranodal localizations of the MCL.